Nestlé Purina, a global leader in pet care, hosted its fourth annual Better with Pets Summit at the Brooklyn Expo Center in New York City on Tuesday, October 18, bringing together pet community experts and leaders across the nation to explore how pets and people are living bigger and better lives thanks to new research and innovation that will shape the future of pet care.
Featuring three interactive panel discussions, the Better with Pets Summit examined topics that continue to affect pet care and wellness including the evolving role of pets and their impact on people’s well-being, nutritional innovation that will allow pets to live healthier lives, and demystifying pet nutrition quality and safety standards.
To view the multimedia release go to:
http://www.multivu.com/players/English/7923051-purina-better-with-pets-2016-summit/
Altimetrik, a business transformation and technology solutions company is unveiling advanced IoT solutions that are set to revolutionize the manufacturing industry.
Manufacturing industry is faced with the challenge of digitally connecting its assets with systems and people, engineering and acting upon the data on the floor to achieve predictive maintenance, precision monitoring & remote management. Altimetrik's Enterprise IoT capabilities make operational intelligence real by connecting machine data to newer business insights & driving meaningful outcomes. Altimetrik has made significant investments in creating IoT specific Research & Innovation Labs which’ve helped the company become a frontrunner in IoT consulting and execution. Altimetrik has been identified among leading IoT solution providers for manufacturing by IDC
Altimetrik is among the new breed of technology companies driving its business model based on the three global mega trends of modernization – Digital, Connected Solutions and Consumer Technologies.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7772051-altimetrik-future-of-enterprise-internet/
While January 1 is the traditional day millions announce their New Year’s Resolutions, research shows only 8% of Americans achieve success. For the fifth year, Life Time, is aiming to help people rethink resolutions and instead make a true, internal commitment to themselves to living a healthy way of life by participating in the Commitment Day 5K Fun Run and Walk. Held at more than 40 Life Time destinations across the U.S. and Canada, Commitment Day empowers individuals, families and communities to start the year on the right foot by marking their pledge with action toward a year of better health. New for 2017, a Virtual 5K is available for anyone in North America to join in. All participants will receive a race bib and commemorative Commitment Day tee shirt. Registration, locations and pricing details are available at www.CommitmentDay.com.
Commitment Weekend kicks off on Friday, Dec. 30 and continues through Monday, Jan. 2, when Life Time will open its doors to everyone – whether a member or not. During each of the four days, Life Time’s 122 destinations will feature a variety of health and fitness experiences and activities for all ages. In addition to the 5K Fun Run and Walk on Jan. 1, people can take part in unique-to-Life Time group fitness, indoor cycle and yoga classes such as Strike, Amp Cycle and Warrior Sculpt, as well as Alpha Training. Life Time’s indoor aquatic centers, basketball courts, rock walls and tennis, racquetball and squash courts will all be open with club-specific programming to help men, women and kids make their commitment even easier by doing activities they love or trying new things that will inspire them in the coming year.
To view the multimedia release go to:
http://www.multivu.com/players/English/7991951-life-time-commitment-day-virtual-5k-fun-run-walk/
Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Blue Plate® Mayonnaise, one of the country’s oldest and most beloved condiment brands, is shaking up the mayonnaise aisle with the industry’s first mayonnaise made with Greek yogurt. Blue Plate Light Mayonnaise with Greek Yogurt (Blue Plate Light Greek) features creamy, tangy Greek yogurt for a full-flavored light mayonnaise with half the fat and calories of traditional mayonnaise, plus one gram of protein per serving. The new Blue Plate Light Greek is in stores now, available in a 30-ounce jar and a 12-ounce squeeze bottle.
This is the first major product innovation in real mayonnaise since the introduction of olive oil more than five years ago. Consumer research shows that Greek yogurt has come into its own as a food super trend, and U.S. consumption is expected to reach $4 billion by 2019. Blue Plate Light Greek features a flavor that is perfectly proportioned to pair with sandwiches, salads and more. The added protein is yet another nutritious benefit not found in any other mayonnaise.
To view the multimedia release go to:
http://www.multivu.com/players/English/7740951-blue-plate-greek-mayo/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
https://youtu.be/_HT-llQ-kmw If you’re a business owner trying to find ways to increase conversions or security or both on your site, you may have found there’s a lot of buzz about how trust seals can help your site. It’s pretty much a given that to have at least a shot at winning the ecommerce game, your site needs a trust seal. But choosing a trust seal that’s both right for you and from a company that can back up its claims takes a little research.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
